Date: 2020-06-16
Type of information: Series B financing round
Company: eTheRNA (Belgium)
Investors: LSP (the Netherlands), PMV (Belgium), Boehringer Ingelheim Venture Fund (Germany), Fund+ (Belgium), Omega Funds (USA), Grand Decade, a BVI subsidiary owned by China Grand Pharmaceutical and Healthcare Holdings Ltd; BNP Paribas Fortis Private Equity (Belgium), Yijing Capital (China), Novalis LifeSciences LLC (USA).
Amount: €34 M
Funding type: series B financing round
Planned used:
Proceeds of the financing will fund continued development and commercialization of proprietary mRNA technologies and a range of therapeutic products. eTheRNA's TriMix platform is a core differentiating component in the Company's product programs and comprises three mRNAs encoding proteins that act together to significantly increase immune responses. TriMix has demonstrated broad application across major cancer types, both preclinically and clinically, offering the prospect of therapeutic vaccines and localised tumor treatments acting synergistically with standard of care treatments. To facilitate its product development activities eTheRNA has developed a proprietary lipid nanoparticle (LNP) platform to enable intravenous delivery of various (neo)antigens, which in combination with TriMix results in unprecedented immune responses. Not only will eTheRNA start clinical development of its internal programs for intravenous mRNA delivery, the Company will also explore partnering opportunities. In infectious diseases, eTheRNA's technologies are being deployed in an eTheRNA-led international consortium which is developing a cross-strain protective SARS-CoV-2 mRNA vaccine for high risk populations.
Others:
Therapeutic area: Immunological diseases - Infectious diseases
